Innovation Pharmaceuticals, Inc.

Company Listings from SPi: Innovation Pharmaceuticals, Inc.

You are here: Home >> SPi Company Listings >> Innovation Pharmaceuticals, Inc.

 

Innovation Pharmaceuticals, Inc.

Website:
http://

Search for other references to "innovation" on SPi News

Latest Innovation Pharmaceuticals, Inc. News

Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program BEVERLY, Mass., March 15, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform...... 12:00 GMT Friday 15th March 2019

Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline BEVERLY, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce...... 15:10 GMT Tuesday 26th February 2019

Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis BEVERLY, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report t...... 14:00 GMT Tuesday 19th February 2019

Innovation Pharmaceuticals Files Form 10-Q Quarterly Report BEVERLY, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February...... 15:45 GMT Monday 11th February 2019

Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX BEVERLY, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, today announces that the C...... 14:30 GMT Thursday 31st January 2019

Innovation Pharmaceuticals Announces Clinical Development Plans for Oral Brilacidin for Inflammatory Bowel Disease BEVERLY, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce pla...... 13:30 GMT Tuesday 22nd January 2019

Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease BEVERLY, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform share...... 13:00 GMT Monday 14th January 2019

Published Studies Confirm Cisplatin Remains Preferred Chemotherapy Component in Head and Neck Cancer Treatment; Innovation Pharmaceuticals on Target with Clinical Trials of Brilacidin for Preventing Severe Oral Mucositis BEVERLY, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform share...... 13:00 GMT Tuesday 8th January 2019

Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate BEVERLY, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, reported today that the U....... 14:00 GMT Wednesday 2nd January 2019

Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis BEVERLY, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the C...... 12:05 GMT Monday 17th December 2018

Buy Innovation Pharmaceuticals, Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us